News

In a wide-ranging analysis of thousands of different proteins from liver samples from transplant patients, a team of scientists in Spain discovered potential links to…

Denifanstat, Sagimet Biosciences’ experimental therapy, outperformed a placebo at resolving nonalcoholic steatohepatitis (NASH) — a severe form of fatty liver disease —…

Rare Liver Diseases Month, observed every February, seeks to call attention to the more than 100 rare liver disorders that affect a significant portion…

Eureka Therapeutics and City of Hope will jointly conduct a Phase 1 clinical trial of assessing Eureka’s investigational CAR T-cell therapy ET1402 for hepatocellular carcinoma (HCC), the most…

ProSciento and OWL Metabolomics are partnering to find eligible participants for clinical trials for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Results from a mouse study of nonalcoholic steatohepatitis were promising for Viking Therapeutics' oral therapy VK2809, now also in a Phase 2 trial.

SIR-Spheres radiation microspheres shrank the tumors of a significantly larger number of liver cancer patients than Nexavar in a Phase 3 trial.

Ocera Therapeutics has started the second part of a Phase 1/2a clinical trial of OCR-002 (ornithine phenylacetate) tablets as a treatment for a liver…

A study by Australia’s Westmead Institute has revealed an unexpected role for zinc in liver disease. Researchers at the institute’s Storr Liver Center showed that…

A new digital support platform, IO Loop, is helping patients stay connected online with doctors before, during, and after treatment. This helps patients track symptoms,…